Synopsis
Foreword Stephen Katz MD, PhD, Director, NIAMS
Foreword A personal view: Luke Evnin, PhD, President, SRF
Preface John Varga, MD, Christopher P. Denton, PhD, FRCP, Fredrick M. Wigley, MD
Section I. Introduction
Chapter 1 - Historical Perspective - Christopher P. Denton, PhD, FRCP, and Carol Black
Chapter 2 - Therapeutic evolution: a professor's view - Frank A. Wollheim, MD, PhD, FRCP
Section II: Epidemiology, Genetics and Classification
Chapter 3 - Overview: Epidemiology, Genetics and Classification - Christopher P. Denton, PhD, FRCP
Chapter 4 - Epidemiology and Environmental Risk Factors - Jammie K. Barnes, MD,
and Maureen D. Mayes, MD, MPH
Chapter 5 - Genetic Factors - Yannick Allanore, MD, PhD, and Filemon K. Tan, MD, PhD
Chapter 6 - Disease Subsets in Clinical Practice - Robyn Therese Domsic, MD, MPH,
and Thomas A. Medsger, Jr., MD
Chapter 7 - Evolving Concepts of Diagnosis and Classification - Lorinda Chung, MD, MS, Jaap Fransen, MD, and Frank H.J. Van den Hoogen, MD, PhD
Chapter 8 - Disease Classification using Molecular Signatures - Michael L. Whitfield, PhD, and Robert Lafyatis, MD
Section III: Scleroderma in Children
Chapter 9 - Juvenile Localized Scleroderma - Francesco Zulian, MD
Chapter 10 - Juvenile Systemic Scleroderma - Ivan Foeldvari, MDSection IV: Other Fibrosing Skin Conditions
Chapter 11 - Scleroderma Mimics -Laura K. Hummers, MD, ScM
Chapter 12 - Localized Forms of Scleroderma in Adults - Amy E. Gilliam, MD, and Anita C. Gilliam, MD, PhD
Chapter 13 - Nephrogenic Systemic Fibrosis - Peter J. Wermuth, PhD, and Sergio A. Jimenez, MD
Section V: Pathogenetic Basis
Chapter 14 - Overview: Integrated Pathogenesis - John Varga, MD
Chapter 15 - Immunological Mechanisms - Francisco Boin, MD, and Carlo Chizzolini, MD
Chapter 16 - Innate Immunity - Keith B. Elkon, MD, and Julia J. Rhiannon, MD, MSW
Chapter 17 - Autoantibodies in Pathogenesis - Kimberly Doering, BS, and Antony Rosen, MB ChB, BSc (Hons)
Chapter 18 - The Clinical Aspects of Autoantibodies - John D. Pauling, BMBS, MRCP, and Neil McHugh, MB, ChB, MD, FRCP, FRCPath
Chapter 19 - Mechanisms of Vascular Disease - Bashar Kalaheh, MD, and Mary Jo Mulligan-Kehoe, PhD
Chapter 20 - Vascular Biomarkers - Laura K. Hummers, MD, ScM
Chapter 21 - Mechanisms of Fibrosis - John Varga, MD
Chapter 22 - Fibrosis: Insights from the stiff skin syndrome - Elizabeth E. Gerber, BS, and Harry C. Dietz, MD
Chapter 23 - Biomarkers of Fibrosis - Christian Beyer, MD, Oliver Distler, MD, and Jörg H.W. Distler, MD
Chapter 24 - Overview of Animal Models - Christopher P. Denton, PhD, FRCP, and Robert Lafyatis, MD
Section
VI: Cardiovascular Manifestations and ManagementChapter 25 - Overview: Cardiovascular Manifestations and Management - Fredrick M. Wigley, MD
Chapter 26 - Raynaud Phenomenon - Arianne Herrick and Fredrick M. Wigley, MD
Chapter 27 - Nailfold Capillaroscopy - Maurizio Cutolo, MD and Vanessa Smith, MD, PhD
28SystemicVascular Disease , MD, PhD, MD, FRCP
Chapter 29 - Scleroderma Renal Crisis - Christopher P. Denton, PhD, FRCP, and Virginia Steen, MD
Chapter 30 - Cardiac Involvement -Sanjiv J. Shah, MD, and André Kahan, MD, PhD
Chapter 31 - Erectile Dysfunction - Edward V. Lally, MD, Arthur L. Burnett, MD, MBA, FACS, and Trinity J. Bivalacqua, MD, PhD
Section VII: Pulmonary manifestations and management
Chapter 32 - Overview: Pulmonary manifestations and management - Christopher P. Denton, PhD, FRCP
Chapter 33 - Clinical Assessment of Lung Disease - Greg J. Keir, MBBS, FRACP, Richard M. Silver, MD, and Athol U. Wells, MD, FRCP
Chapter 34 - Computerized Tomography of Interstitial Lung Disease - Athol U. Wells, MD, FRCP, and Jonathan Goldin MD,
"synopsis" may belong to another edition of this title.
